Aurinia Pharmaceuticals Inc.
AUPH
$14.07
-$0.01-0.07%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/19/2026
-
Tickeron - Technical Analysis
3/19/2026
-
Tickeron - Technical Analysis
3/18/2026
-
Tickeron - Technical Analysis
3/17/2026
-
Tickeron - Stocks
3/17/2026
-
Tickeron - Stocks
3/17/2026
-
Tickeron - Stocks
3/14/2026
-
Tickeron - Stocks
3/13/2026
-
Tickeron - Stocks
3/12/2026
-
MarketBeat
Aurinia Pharmaceuticals (AUPH, $14.81) price moved above its 50-day Moving Average on March 11, 2026
3/12/2026
-
Tickeron - Technical Analysis
3/11/2026
-
MarketBeat
3/11/2026
-
Tickeron - Stocks
3/11/2026
-
Tickeron - Stocks
3/10/2026
-
Simply Wall St
3/10/2026
-
Tickeron - Stocks
3/9/2026
-
Simply Wall St
3/7/2026
-
Simply Wall St
3/7/2026
-
Tickeron - Stocks
3/7/2026
-
Tickeron - Stocks
3/7/2026
-
Tickeron - Stocks
3/6/2026
-
SeekingAlpha
3/6/2026
-
Seeking Alpha - Healthcare
3/6/2026
-
Tickeron - Stocks
3/6/2026
-
Tickeron - Stocks
3/6/2026
-
Simply Wall St
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, February 26, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
250 744 2487
Address
#140, 14315 – 118 Avenue
Edmonton, AB T5L 4S6
Edmonton, AB T5L 4S6
Country
Year Founded
Business Description
Sector
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan...
more